Categories
Blood Cancer

CAR-T in multiple myeloma: cilta-cel & ide-cel [Video]

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on how the addition of ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel) to the treatment paradigm is adding value to the treatment of patients with multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

Mapping the Therapeutic Odyssey in Multiple Myeloma [Video]

Chair, Nina Shah, MD, Katharina E. Ganapathi, BSN, RN, OCN, and Mandy Robertson, MD, CPE, discuss multiple myeloma in this CME/MOC/NCPD activity titled “Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/MZJ865. CME/MOC/NCPD credit will be available until May 8, 2023.

Categories
Blood Cancer

The impact of the approval of cilta-cel in multiple myeloma [Video]

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on chimeric antigen receptor T-cell (CAR-T) therapies in multiple myeloma, commenting on the recent approval of ciltacabtagene autoleucel (cilta-cel). The first CAR-T product was approved in pediatric and young adult patients with acute lymphoblastic leukemia (ALL), and its use was later expanded to treat a larger number of indications. The first CAR-T product in multiple myeloma, idecabtagene vicleucel, was approved in 2021 based on the results of the KarMMa trial (NCT03361748). More recently, the highly promising results from the CARTITUDE-1 trial (NCT03548207) led to the approval of cilta-cel by the FDA. According to Prof. Mohty, the addition of cilta-cel to the treatment armamentarium in multiple myeloma will undoubtedly improve the outcomes of patients with R/R disease, and he believes that CAR-Ts will start being used in earlier lines of treatment. Several trials are already comparing CAR-T products versus existing standards of care (SOC) in myeloma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

Categories
Blood Cancer

Advances in CAR-T therapy for R/R multiple myeloma: ide-cel & cilta-cel [Video]

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the efficacy and promise of BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) in relapsed/refractory (R/R) multiple myeloma. Ide-cel was approved in March 2021 for patients with R/R multiple myeloma based on the results of the Phase II KarMMA study (NCT03361748) which reported a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months. The field of CAR-T therapies for multiple myeloma is rapidly evolving, notably with cilta-cel, which showed remarkable results in the Phase Ib/II CARTITUDE-1 trial (NCT03548207), with an overall response rate (ORR) of almost 98% and a 2-year PFS of 71%. In addition, the incidence of severe cytokine release syndrome (CRS) and neurotoxicity was low. These trials highlight the potency of BCMA-directed CAR-T therapies for R/R multiple myeloma and several clinical trials are now evaluating these approaches in earlier lines of treatment. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.

Categories
Blood Cancer

The future of CAR-T therapy for multiple myeloma [Video]

Niels van de Donk, MD, PhD, VU University Medical Center, Amsterdam, Netherlands, talks on the development of CAR T-cell therapy for multiple myeloma. Over recent years, substantial evidence has been gathered to support the use of CAR-T therapy in heavily pretreated patients. Most recently, these efforts led to the FDA approval of idecabtagene vicleucel (ide-cel) for people with multiple myeloma that has relapsed after or is refractory to at least four prior treatments. Ciltacabtagene autoleucel (cilta-cel), another BCMA-directed therapy with two BCMA-targeting single-domain antibodies designed to confer avidity, is also under FDA review and is expected to be approved in the coming months. Prof. van de Donk comments on continued investigations driving the field forwards, including the assessment of new constructs, and testing in earlier stages of disease. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

Real world use of CAR T-cell therapy in multiple myeloma [Video]

Idecabtagene vicleucel (ide-cel) is a chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma who have undergone 4 or more prior therapies. Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the number of patients who are able to receive ide-cel. Data from the Flatiron Health Electronic Health Record (EHR) suggests fewer than 15% of patients are eligible for treatment, with a number of patients dying before being eligible. Dr Costa thus highlights the need to approve CAR T-cell therapies for earlier lines of treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

CAR-T therapy in multiple myeloma: research blind spots [Video]

CAR T-cell therapy has been shown to elicit high-quality responses in patients with multiple myeloma. Positive data from the pivotal Phase II KarMMa trial led to the approval of idecabtagene vicleucel, a BCMA-directed CAR T-cell therapy, in patients with heavily pretreated relapsed/refractory myeloma, and ongoing trials are investigating the utility of CAR-T versus standard of care regimens in earlier lines of treatment. Andrew Cowan, MD, University of Washington, Seattle, WA, discusses the blind spots in myeloma CAR-T research, highlighting key topics such as treatment sequencing, combination studies, and retreatment with BCMA-targeted therapies. This interview took place at during 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

The role of immunotherapy in multiple myeloma [Video]

Nina Shah, MD, University of California, San Francisco, CA, provides her insights on the future of multiple myeloma treatment. Multiple advancements have been made in recent years, especially with the development of immunotherapies. In addition to existing monoclonal antibodies such as daratumumab and isatuximab, chimeric antigen receptor (CAR) T-cell therapies including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) represent alternative therapies for patients with relapsed/refractory multiple myeloma. Dr Shah additionally highlights the development of bispecific T-cell engagers (BiTEs), as well moving immunotherapies into the frontline setting. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.